Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 36763945

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 May 10
First author
Buske C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Aug 20;41(24):4059-4060. doi: 10.1200/JCO.23.00649.
    note
    Source null
    related pmid
    37348023
    relationship
    Comment in

Authors and identifiers

  1. name
    Buske C
    type
    Author
  2. name
    Dimopoulos MA
    type
    Author
  3. name
    Grunenberg A
    type
    Author
  4. name
    Kastritis E
    type
    Author
  5. name
    Tomowiak C
    type
    Author
  6. name
    Mahé B
    type
    Author
  7. name
    Troussard X
    type
    Author
  8. name
    Hajek R
    type
    Author
  9. name
    Viardot A
    type
    Author
  10. name
    Tournilhac O
    type
    Author
  11. name
    Aurran T
    type
    Author
  12. name
    Lepretre S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Buske C
    type
    Author
  2. name
    Dimopoulos MA
    type
    Author
  3. name
    Grunenberg A
    type
    Author
  4. name
    Kastritis E
    type
    Author
  5. name
    Tomowiak C
    type
    Author
  6. name
    Mahé B
    type
    Author
  7. name
    Troussard X
    type
    Author
  8. name
    Hajek R
    type
    Author
  9. name
    Viardot A
    type
    Author
  10. name
    Tournilhac O
    type
    Author
  11. name
    Aurran T
    type
    Author
  12. name
    Lepretre S
    type
    Author
bibliography ids
  1. nci-bib-bd50669d081e7d17288772d2
book metadata
content sha256
9daa1bfb26c828c0a0d70e362ad1b6228bd1a0ca9f93e5940e069e7d40aee8a4
document type
citation
dois
  1. 10.1200/JCO.22.01805
electronic publication date
display
2023 Feb 10
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:36763945
immutable id
pubmed:36763945@9daa1bfb26c828c0a0d70e362ad1b6228bd1a0ca9f93e5940e069e7d40aee8a4
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
14
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2607-2616
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Aug 20;41(24):4059-4060. doi: 10.1200/JCO.23.00649.
    note
    Source null
    related pmid
    37348023
    relationship
    Comment in
outcomes validated
false
pmid
36763945
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
61ea77df938d9e0ec9facadc3664e6a746df2f3d482aba84202bb5806400f0ae
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 May 10
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Journal Article
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36763945/
title
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Preserved source evidence · Independent clinical review pending · Not medical advice